A meta-analysis of CXCL12 expression for cancer prognosis

Samarendra, Harsh; Jones, Keaton; Petrinic, Tatjana; Silva, Michael A.; Reddy, Srikanth; Soonawalla, Zahir; Gordon-Weeks, Alex

doi:10.1038/bjc.2017.134

Cited by 80 publications

(81 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The encoded protein exerts its function by binding with chemokine receptor 4 (CXCR4), a G protein-coupled receptor, in various biological processes, including embryogenesis, inflammatory response, and tumor progress and metastasis. Pathological roles for the CXCR4/CXCL12 axis have been demonstrated in various cancers, including breast cancer [81], kidney carcinoma [82], bone sarcoma [83], and NSCLC [84, 85]. CXCR4/CXCL12 overexpression in these malignancies as well as in NSCLC may facilitate the local infiltration and dissemination of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

Cen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Since the function of microRNA (miR)-210 in non-small cell lung cancer (NSCLC) remains unclear, we aimed to explore the clinical significance of miR-210 in NSCLC. Methods: NSCLC-related data from 1673 samples on Gene Expression Omnibus and 1090 samples on The Cancer Genome Atlas were obtained and analyzed. The expression level of miR-210 was validated via real-time quantitative PCR analysis with 125 paired clinical samples. A meta-analysis was performed to generate a comprehensive understanding of miR-210 expression and its clinical significance in NSCLC. In addition, bioinformatics analysis was also conducted to reveal the potential underlying mechanism of miR-210 action in NSCLC. Results: miR-210 expression was consistently elevated in NSCLC solid tissue samples. However, its expression was controversial in easily obtained body fluids (i.e., blood, plasma, and serum). Moreover, an overall pooled meta-analysis implied a comparatively higher level of miR-210 expression in NSCLC cancerous tissue than in normal control tissue (P < 0.001). In addition, a meta-analysis of outcome revealed a significant diagnostic capacity of miR-210 in NSCLC by detecting its expression in serum and sputum (area under the summary receiver operating characteristic curve 0.82 and 0.81, respectively). miR-210 overexpression was associated with poor progression-free survival (PFS) in NSCLC and was negatively related to overall survival and disease-free survival. Bioinformatic gene enrichment and annotation analyses showed that the target genes of miR-210 were greatly enriched in cell adhesion and plasma membrane, and three pathways were considered to be the main functional circuits of miR-210: renin secretion, the cGMP-PKG signaling pathway, and cell adhesion molecules. Conclusion: In NSCLC, miR-210 expression was elevated and overexpression indicated poor PFS. Expression level of miR-210 in serum and sputum showed significant diagnostic value for NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

Cen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…The instructive role for CXCL12, a stroma‐derived growth factor in facilitating optic glioma growth through reduction of cAMP, has been demonstrated in mouse models. This suggests that CXCL12 could be further evaluated as a therapeutic target . Research efforts should continue to identify additional chemokines and growth factors for potential stroma‐directed glioma therapies.…”

Section: Future Directions For Nf1‐associated Opg Researchmentioning

confidence: 99%

“…This suggests that CXCL12 could be further evaluated as a therapeutic target. 56,57 Research efforts should continue to identify additional chemokines and growth factors for potential stroma-directed glioma therapies.…”

Section: Direction Of Future Clinical Trialsmentioning

confidence: 99%

Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights

Khatua

Gutmann

Packer

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Children with neurofibromatosis type 1 (NF1) are predisposed to develop central nervous system neoplasms, the most common of which are low-grade gliomas (LGGs). The absence of human NF1 associated LGG-derived cell lines, coupled with an inability to generate patient-derived xenograft models, represents barriers to profile molecularly targeted therapies for these tumors. Thus, genetically engineered mouse models have been identified to evaluate the interplay between Nf1-deficient tumor cells and nonneoplastic stromal cells to evaluate potential therapies for these neoplasms. Future treatments might also consider targeting the nonneoplastic cells in NF1-LGGs to reduce tumor growth and neurologic morbidity in affected children.

show abstract

“…Despite the association of the CXCL12/CXCR4 pathway with several poor prognostic factors in patients with cervical cancer, including hypoxia, reports of the association between pre‐treatment CXCL12 or CXCR4 tumour expression and the survival of patients with cervical cancer are conflicting and hard to interpret. This, in part, is because of variability in patient characteristics and the type of treatment that they received, as well as the absence of a standardized and validated method for measuring CXCL12 and CXCR4 expression . Nevertheless, the accumulating evidence implies important but complex relationships between the CXCL12/CXCR4 pathway and cervical cancer development and progression, making it a potential target for therapeutic intervention.…”

Section: Cxcl12/cxcr4 and Cervical Cancer Pathogenesismentioning

confidence: 99%

“…There is an important need to identify biomarkers of response to RTCT and Plerixafor in women with cervical cancer. Pre‐treatment tumour CXCL12 or CXCR4 expression levels may prove helpful in this regard, although these markers do not appear to be strong predictors of outcome in cervical cancer . It may be more relevant to explore biomarkers of CXCL12/CXCR4 upregulation during RTCT using serial tumour biopsies, serial measurement of circulating CXCL12 levels or serial MR imaging to assess changes in myeloid cell accumulation or tumour perfusion .…”

Section: Opportunities and Future Directionmentioning

confidence: 99%

Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer

Lecavalier-Barsoum

Chaudary

Han

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Approximately half of cervical cancer patients present with locally advanced disease, for which surgery is not an option. These cases are nonetheless potentially curable with radiotherapy and cisplatin chemotherapy. Unfortunately, some tumours are resistant to treatment, and lymph node and distant recurrences are major problems in patients with advanced disease at diagnosis. New targeted treatments that can overcome treatment resistance and reduce metastases are urgently needed. The CXCL12/CXCR4 chemokine pathway is ubiquitously expressed in many normal tissues and cancers, including cervical cancer. Emerging evidence indicates that it plays a central role in cervical cancer pathogenesis, malignant progression, the development of metastases and radiation treatment response. Pre-clinical studies of standard-of-care fractionated radiotherapy and concurrent weekly cisplatin plus the CXCR4 inhibitor Plerixafor (AMD3100) in patient-derived orthotopic cervical cancer xenografts have shown improved primary tumour response and reduced lymph node metastases with no increase in early or late side effects. These studies have pointed the way forward to future clinical trials of radiotherapy/cisplatin plus Plerixafor or other newly emerging CXCL12 or CXCR4 inhibitors in women with cervical cancer.

show abstract

A meta-analysis of CXCL12 expression for cancer prognosis

Cited by 80 publications

References 62 publications

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights

Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer

Contact Info

Product

Resources

About